Skip to main content
Premium Trial:

Request an Annual Quote

New Oncology, National Cancer Centre Singapore to Collaborate on Cancer Dx

NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration to help the National Cancer Centre Singapore offer personalized cancer treatment using the company's proprietary diagnostic platform, Neo.

Neo enables physicians to optimize treatment for their patients by providing a tumor profile showing all types of therapeutically relevant genetic alterations, including mutations, amplifications, insertions and deletions, as well as novel and known translocations, the firm said in a statement.

Andreas Jenne, CEO of New Oncology, said that the deal is a major milestone in the firm's international business expansion. Financial and other details of the agreement were not disclosed.

New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, is based in Cologne, Germany. Its NeoPlus pan-cancer diagnostic test reliably detects genetic alterations from a single patient sample with short turn-around times.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.